A carregar...
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
Sipuleucel-T is an autologous cell immunotherapy for castrate-refractory prostate cancer, with US Food and Drug Administration (FDA) approval in asymptomatic or minimally symptomatic prostate cancer. In this review we address the background of prostate cancer incidence and other available therapy on...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3143908/ https://ncbi.nlm.nih.gov/pubmed/21792315 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S14107 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|